Plaque stabilization by intensive LDL-cholesterol lowering therapy with atorvastatin is delayed in type 2 diabetic patients with coronary artery disease—Serial angioscopic and intravascular ultrasound analysis  by Takayama, Tadateru et al.
OP
a
d
T
J
J
A
a
b
c
d
e
f
g
h
i
a
A
R
R
2
A
A
K
T
A
A
I
D
U
8
(
0
hJournal of Cardiology 61 (2013) 381–386
Contents lists available at SciVerse ScienceDirect
Journal  of  Cardiology
jo ur nal home page: www.elsev ier .com/ locate / j j cc
riginal  article
laque  stabilization  by  intensive  LDL-cholesterol  lowering  therapy  with
torvastatin  is  delayed  in  type  2  diabetic  patients  with  coronary  artery
isease—Serial  angioscopic  and  intravascular  ultrasound  analysis
adateru  Takayama  (MD)a,∗, Takafumi  Hiro  (MD,  FJCC)a, Yasunori  Ueda  (MD,  FJCC)b,
unko Honye  (MD,  FJCC)c,  Sei  Komatsu  (MD,  FJCC)d, Osamu  Yamaguchi  (MD)e,  Yuxin  Li  (MD)f,
unji  Yajima  (MD)g, Kenji  Takazawa  (MD,  FJCC)h,  Shinsuke  Nanto  (MD,  FJCC) i, Satoshi  Saito  (MD)a,
tsushi  Hirayama  (MD,  FJCC)a, Kazuhisa  Kodama  (MD,  FJCC)d
Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
Cardiovascular Division, Osaka Police Hospital, Osaka, Japan
Department of Cardiology, Fuchu Keijinkai Hospital, Fuchu, Japan
Cardiovascular Center, Amagasaki Central Hospital, Amagasaki, Japan
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan
Department of Advanced Cardiovascular Imaging, Nihon University School of Medicine, Tokyo, Japan
Department of Cardiology, The Cardiovascular Institute Hospital, Tokyo, Japan
Department of Cardiology, Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan
Department of Advanced Cardiovascular Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 2 August 2012
eceived in revised form
9 November 2012
ccepted 21 January 2013
vailable online 9 March 2013
eywords:
WINS
ngioscopy
torvastatin
ntravascular ultrasound
a  b  s  t  r  a  c  t
Background:  Diabetes  mellitus  (DM)  is a  major  risk  factor  for cardiovascular  events.  The  study  purpose  was
to  compare  DM  and  non-DM  (nDM)  patients  in terms  of statin-induced  change  of plaque  characteristics
using  intravascular  ultrasound  (IVUS)  and  coronary  angioscopy.
Methods:  Patients  with  coronary  artery  disease  and  hypercholesterolemia  who  were  enrolled  to  the
TWINS  were  selected  and  classiﬁed  into  two  groups:  DM group  and  nDM  group.  Eleven DM  patients
and  28  nDM  patients  were studied.
Results:  Low-density  lipoprotein  cholesterol  levels  decreased  signiﬁcantly  to a similar  extent  at  weeks  28
and 80  from  baseline  in DM  and  nDM  (p <  0.001).  The  mean  angioscopic  color grades  of yellow  plaques
in  DM and nDM  were  similar  at baseline  and  signiﬁcantly  decreased  at week  80 from  baseline  in both
groups,  however,  the  mean  change  of angioscopic  color  grade  from  baseline  in DM  were  not  signiﬁcantly
decreased  and  the  mean  angioscopic  color  was  signiﬁcantly  higher  than  that in nDM  (1.34  vs. 1.00,iabetes mellitus p  <  0.05)  at  week  28.  IVUS  showed  plaque  volume  reduction  in  both  groups  (p < 0.01)  except  at  week  80
in  DM  group,  which  was  not  statistically  signiﬁcant  different  compared  to the  baseline.
Conclusion:  In DM  patients,  plaque  volume  regression  by atorvastatin  was shown  to  be  attenuated,  and  its
color  improvement  was  signiﬁcantly  delayed.  However,  the  yellowness  became  comparable  between  DM
and nDM  groups  at week  80. These  results  indicate  that  patients  with  DM  should  be treated  by  intensive
lipid-lowering  therapy  with  atorvastatin  for  at least  80  weeks  to stabilize  vulnerable  plaque.© 2013  Jap
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Introduction
Our previous study (TWINS: evaluation with simultaneous angio-
scopic and intravascular ultrasound study) indicated by serial
observations using intravascular ultrasound (IVUS) and angioscopy
that intensive lipid-lowering therapy with atorvastatin might
reduce cardiac events via reduction of plaque vulnerability [1].
The study demonstrated that low-density lipoprotein-cholesterol
(LDL-C) lowering below 100 mg/dL by statin was associated with
early improvement in yellow color in vulnerable yellow plaques,
possibly indicating plaque stabilization, and with subsequent
vier Ltd. All rights reserved.
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laque volume regression, in patients with coronary artery disease
CAD). The data suggested that the stabilization and the volume
egression of plaque might occur in non-parallel ways.
Diabetes mellitus (DM) is a high risk factor for coronary
therosclerosis and increases the incidence of cardiovascular
vents. Moreover, the UK Prospective Diabetes Study reported that
ntensive blood glucose control with sulfonylurea or insulin attenu-
tes the progression of microangiopathy, but not macroangiopathy
2]. It has also been reported that LDL-C level is a major risk factor
or CAD in DM patients [3]. In addition to the blood glucose level,
oth hyperinsulinemia and enhanced inﬂammatory reaction have
mportant roles in future cardiovascular events in patients with DM
4]. The presence of DM is considered to be an equivalent risk fac-
or of cardiovascular outcome, compared to the existence of past
istory of signiﬁcant CAD [5]. Furthermore, DM patients have high
ikelihood of in-stent restenosis [6,7].
The anti-atherosclerotic efﬁcacy of statins has been proved in
any studies assessed by using IVUS as well as coronary angioscopy
8–13].
Various multicenter studies have revealed that intensive lower-
ng of LDL-C level by statin administration reduces plaque volume
n patients with stable CAD or acute coronary syndrome [14–16].
Some previous studies have revealed that color grade of plaque
an be reduced by statins [17–24]. Among them, the TWINS we  pre-
iously performed was a multicenter trial that used both IVUS and
ngioscopy to assess the effect of atorvastatin on the plaque volume
s well as plaque stability. The study demonstrated early attenua-
ion of angioscopic yellow color in plaques receiving atorvastatin
10–20 mg/day), followed by subsequent plaque volume regression
hich was relatively delayed compared to the color change. The
urpose of this sub-analysis of the TWINS was to elucidate whether
iabetes mellitus inﬂuences the degrees of stabilization and volume
egression of yellow plaques in patients recruited in the TWINS.
ethods
tudy protocol and population
The detailed methods have been described in the main paper
f the TWINS [1]. Brieﬂy, enrolled patients with CAD complicated
y hypercholesterolemia with a fasting LDL-C level ≥120 mg/dL
eceived a daily dose of oral atorvastatin 10–20 mg/day for 80
eeks. Immediately after coronary angiography, coronary yellow
laques of interest were selected and evaluated with coronary
ngioscopy and IVUS at weeks 0 (baseline), 28, and 80. The patients
ith one or more yellow plaques over or equal to grade 2 were
nrolled.
Among 57 patients enrolled in the TWINS, 38 patients were fol-
owed to 28 weeks and 31 patients were followed to 80 weeks. The
esults of the angioscopy and IVUS images observed simultaneously
t these three time points for all plaques were reported previously.
n this sub-study, DM was  diagnosed by the attending physicians,
nd the patients were divided into 2 groups: DM group and non DM
roup (nDM). We  further compared and analyzed these two  groups
y using the data of both angioscopy and IVUS images at these three
valuation time points of baseline and weeks 28 and 80. This proto-
ol was approved by the Institutional Review Board of Osaka Police
ospital and Nihon University Itabashi Hospital. All participants
rovided written informed consent before participation.
ntravascular imagings (angioscopy and IVUS)ngioscopic examination
Immediately after coronary angiography, baseline angioscopic
mages were obtained with a Fiber Imaging System FT-201
FiberTech Co Ltd, Tokyo, Japan), using a previously describeddiology 61 (2013) 381–386
technique [7]. From these images, yellow color lesions (the color
grade was 2 or more) located in major coronary arteries were
selected for the main angioscopic examination. The color grade
of the enrolled plaque was  determined by the attending operator
in the catheterization laboratory of the participating hospital, and
then reconﬁrmed by the central committee of the TWINS [1]. The
positions of the plaques were conﬁrmed with ﬂuoroscopy by deter-
mining the location of the ﬁberscope tip, and plaque maps were
prepared. Images were recorded on a digital videotape and graded
using a 6-point scale: 0, not yellow at all; 1, pale yellow; 2, yellow;
3, deep yellow; 4, bright yellow; and 5, ruptured plaque. At weeks
28 and 80, the same positions as at baseline were observed with
angioscopy in reference to the positions of side branches used as
landmarks. Average of all color grades at baseline, weeks 28, and
80 in each patient were calculated.
IVUS image acquisition
IVUS was  performed with a 2.6F 40-MHz Atlantis Pro IVUS
catheter (Boston Scientiﬁc Corporation, Natick, MA,  USA). The IVUS
probe was advanced to a side branch located distal to the target
lesion, and images were obtained during automatic pullback at a
rate of 0.5 mm/s  and recorded on s-VHS videotape. Based on the
plaque map, the IVUS volumetric analyses of the target lesions
were conducted using a 20-mm segment (IVUS analysis segment) at
lesion sites as the unit of analysis. The boundary of the lumen and
external elastic membrane (EEM) was traced semi-automatically
on digitized cross-sections of the IVUS analysis segment every
0.1 mm (Netra IVUS, Ver.2.04, ScImage, Inc., Los Angeles, CA, USA).
At the baseline examination, the IVUS analysis segment was deter-
mined to include a yellow colored position detected by angioscopy,
based on the plaque map  and the position of a side branch. At the
examinations performed in weeks 28 and 80, the IVUS analysis seg-
ment was  set using a side branch as a landmark to ensure that at
the 3 time points the same position was  imaged by IVUS. Averages
of plaque volume, vessel volume, and lumen volume of all plaques
at baseline, weeks 28, and 80 in each patient were calculated.
Statistical analysis
Numerical data were presented as the mean ± standard devi-
ation (SD). Hemoglobin (Hb) A1c was indicated by National Gly-
cohemoglobin Standardization Program equivalent value (Japan
Diabetes Society value + 0.4%). According to whether data were
numerical or categorical, unpaired t-test or Fisher’s exact test was
employed for the comparison of baseline characteristics. The paired
t-test was  employed for intergroup comparison of plaque, vessel,
and lumen volumes. Wilcoxon signed ranks test was  employed
for intergroup comparison of the color grade. For intergroup com-
parison, unpaired t-test was  employed for IVUS measurement and
Wilcoxon ranks test was  for the color grade. In all tests, p < 0.05
(2-sided) was  considered signiﬁcant. Bonferroni’s adjustment was
applied in case of multiple comparison, p < 0.025 (2-sided) was  con-
sidered signiﬁcant. All statistical analyses were performed with the
SAS statistical software package version 9.1 (SAS Institute Inc., Cary,
NC, USA).
Results
Patient characteristics
Baseline characteristics of patients in both DM and nDM groups
are shown in Table 1. A total of 11 DM patients and 28 nDM patients
were studied. There were no signiﬁcant differences between the
two groups with regard to gender, body mass index, and coronary
risk factors except for type of dyslipidemia and the level of HbA1c.
Changes in serum lipids and high-sensitivity C-reactive peptide
(hs-CRP) are shown in Table 2. LDL-C levels in the nDM group were
T. Takayama et al. / Journal of Car
Table  1
Baseline characteristics.
nDM (n = 28) DM (n = 11) p-Value
Age (years) 58.9 ± 8.7 59.7 ± 7.4 0.781
Gender (male/female) (male %) 20/8 (71.4) 9/2 (81.8) 0.693
Body mass index (kg/m2) 23.9 ± 2.3 25.8 ± 4.2 0.085
Type of dyslipidemia 0.016
IIa  16 (57.1) 1 (9.1)
IIb 6 (21.4) 4 (36.4)
Others 6 (21.4) 6 (54.5)
Heart disease (not variant angina) 26 (92.9) 10 (90.9) 1.000
Hypertension 16 (57.1) 7 (63.6) 1.000
Statin pre-treatment 2 (7.1) 2 (18.2) 0.562
Current smoker 4 (14.3) 1 (9.1) 0.765
Concomitant drugs
Aspirin 27 (96.4) 11 (100) 0.525
Antiplatelet agents (except aspirin) 23 (82.1) 9 (81.8) 0.981
ACEI 13 (46.4) 2 (18.2) 0.103
ARB  6 (21.4) 4 (36.4) 0.336
Beta-blockers 7 (25.0) 3 (27.3) 0.884
Anti-diabetes therapy –
None 28 (100) 6 (54.5)
Diet 5 (45.6)
BG + TZD 1 (9.1)
BG + SU 1 (9.1)
Insulin 3 (27.3)
HbA1ca 5.2 ± 0.4 6.4 ± 1.2 <0.001
Data are the number (%) or mean ± SD. Unpaired t-test or Fisher’s exact test were
employed for the tests between groups.
Beta-blockers include alpha/beta-blockers; ACEI, angiotensin-converting enzyme
inhibitor; ARB, angiotensin II receptor blocker; nDM, non-diabetes mellitus; DM,
diabetes mellitus; BG, biguanide; TZD, thiazolidinedione; SU, sulfonylurea.
a National Glycohemoglobin Standardization Program equivalent value (Japan
Diabetes Society value + 0.4%).
Table 2
Changes in serum lipids and hs-CRP.
Baseline (n) p-Value
(nDM vs DM)
Week 28 (n)
[% change]
p-Value
(vs baseline
LDL-C (mg/dL)
nDM 152.2 ± 26.1 (28)
0.002†
85.1 ± 18.5 (28)
[−42.81 ± 14.97%]
<0.001*
DM 123.8 ± 13.9 (11) 74.9 ± 16.1 (11)
[−39.15 ± 12.71%]
<0.001*
TC (mg/dL)
nDM 215.6 ± 29.6 (28)
0.008†
148.9 ± 23.7 (28)
[−30.30 ± 11.49%]
<0.001*
DM  188.5 ± 18.3 (11) 136.9 ± 17.8 (11)
[−26.64 ± 12.16%]
<0.001*
HDL-C (mg/dL)
nDM 40.5 ± 9.4 (28)
0.698
47.1 ± 8.1 (28)
[19.39 ± 20.66%]
<0.001*
DM  39.1 ± 11.9 (11) 43.5 ± 11.9 (11)
[13.75 ± 24.01%]
0.099 
TG  (mg/dL)
nDM 118.5 ± 64.2 (28)
0.260
109.5 ± 51.2 (28)
[27.74 ± 116.81%]
0.474
DM  146.0 ± 76.3 (11) 115.0 ± 36.8 (11)
[−9.20 ± 35.89%]
0.195 
hsCRP (mg/dL)
nDM 0.14 ± 0.18 (28)
0.289
0.16 ± 0.32 (28)
[62.12 ± 306.79%]
0.288
DM  0.07 ± 0.03 (11) 0.06 ± 0.09 (11)
[−9.94 ± 118.01%]
0.148 
Values are the mean ± SD. Paired t-test is employed for values vs. baseline except for hsC
HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; 
nDM,  non-diabetes mellitus; DM,  diabetes mellitus.
* p < 0.025 is signiﬁcant with Bonferroni adjustment: Wilcoxon signed ranks test is em
† p < 0.05 is signiﬁcant: tests for between group comparisons used unpaired t-test for lidiology 61 (2013) 381–386 383
signiﬁcantly higher than in the DM group at baseline (p = 0.002).
LDL-C decreased signiﬁcantly to a similar extent in both groups
at weeks 28 and 80 (p < 0.001, respectively). At week 80, the level
of LDL-C was signiﬁcantly lower in the DM group than in the nDM
group (p = 0.018). At week 80, there was  no difference in LDL-C level
between both groups. High-density lipoprotein cholesterol (HDL-C)
level increased signiﬁcantly in the nDM group both at weeks 28 and
80 (p < 0.001 and p = 0.001, respectively). However there was  no sig-
niﬁcant difference in HDL-C level between both groups at baseline,
weeks 28 and 80. The level of triglycerides showed no signiﬁcant
change in either group both at weeks 28 and 80. hs-CRP decreased
signiﬁcantly in the nDM group at week 80 (p = 0.001). There were
no differences in hs-CRP in both groups between baseline and week
28. However, hs-CRP in the DM group was  signiﬁcantly higher than
in the nDM group at week 80 of the study.
Angioscopic analysis
Angioscopic ﬁndings are shown in Fig. 1. The color grade of the
plaque did not have a statistical difference at baseline between the
two groups. At week 28 the color grade of plaque was signiﬁcantly
improved in the nDM group, but not in the DM group. In addition,
the color grade of the DM group was signiﬁcantly higher than that
in the nDM group at week 28. However, this signiﬁcant difference
in the color grade disappeared at week 80. Finally, there was no
signiﬁcant difference in the color grade between both groups at
week 80.
IVUS analysisIVUS ﬁndings are shown in Table 3. Plaque volume decreased
signiﬁcantly at week 28 in both groups and at week 80 in the nDM
group (p < 0.001, respectively), compared to the baseline. There was
no signiﬁcant difference in change in plaque volume between both
)
p-Value
(nDM vs DM)
Week 80 (n)
[% change]
p-Value
(vs baseline)
p-Value
(nDM vs DM)
0.118
92.0 ± 11.7 (23)
[−38.62 ± 12.71%]
<0.001*
0.018†
78.2 ± 20.6 (11)
[−36.69 ± 16.03%]
<0.001*
0.139
153.3 ± 20.4 (23)
[−28.38 ± 10.46%]
<0.001*
0.112
139.8 ± 26.7 (11)
[−25.31 ± 15.36%]
<0.001*
0.272
45.9 ± 9.9 (23)
[21.61 ± 27.28%]
0.001*
0.415
42.5 ± 14.3 (11)
[8.55 ± 14.63%]
0.055
0.746
113.0 ± 66.3 (23)
[11.73 ± 82.63%]
0.357
0.305
142.9 ± 100.0 (11)
[12.65 ± 81.76%]
0.938
0.268
0.06 ± 0.10 (23)
[−43.64 ± 50.03%]
0.001
0.027
0.22 ± 0.34 (11)
[265.38 ± 521.95%]
0.309
RP.
LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides;
ployed for hsCRP.
pid parameters and Wilcoxon signed ranks test for hsCRP.
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Fig. 1. Changes in the angioscopic color grade. Values are the mean ± SD. Wilcoxon
signed ranks test is employed vs. baseline (*p < 0.025 is signiﬁcant with Bonferroni
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gure legend, the reader is referred to the web  version of this article.)
roups during weeks 28 and 80. In addition, there was  no signiﬁ-
ant difference of change in EEM and lumen volume between both
roups at every follow-up examination.
iscussion
The present study revealed that both stabilizing and regressive
ffects of atorvastatin administered for 80 weeks in patient with
AD was different between the DM and the nDM patients. The color
rade observed by angioscopy is reported to be correlated with
laque stability and a lower yellow (whitish) color is associated
ith more stable plaque [25–27].
Therefore, it is suggested from the present study that the sta-
ilization effect of plaque by statin might be attenuated in DM
atients compared to nDM patients. The main ﬁndings of the
WINS showed non-parallel characteristics in the effects of statin
n plaque stabilization and its volume regression. This sub-study
uggested that some speciﬁc mechanisms of plaque stabilization
ere selectively inhibited in patients with DM.  Less regressive
able 3
hanges in external elastic membrane volume, luminal volume, and plaque volume.
Baseline (n) p-Value (nDM
vs DM)
Week 28 (n) [%
change]
p-Value (vs
baseline)
Plaque volume (mm3)
nDM 136.25
± 30.21 (25) 0.110
126.64 ± 32.19 (25)
[−7.40 ± 8.92%]
<0.001*
DM  156.72
± 37.03 (9)
140.69 ± 41.15 (9)
[−10.24 ± 7.89%]
0.005*
EEM  volume (mm3)
nDM 345.18
± 72.95 (25) 0.869
325.68 ± 69.37 (25)
[−5.44 ± 7.20%]
0.001*
DM  349.82
± 67.95 (9)
328.59 ± 66.82 (9)
[−5.67 ± 4.60%]
0.0031*
Lumen volume (mm3)
nDM 208.93
± 69.30 (25) 0.534
199.05 ± 56.10 (25)
[−2.34 ± 12.60%]
0.105
DM  193.11
± 48.83 (9)
187.90 ± 48.67 (9)
[−2.70 ± 6.09%]
0.143 
alues are the mean ± SD. Paired t-test was employed for values vs. baseline except for h
DM, non-diabetes mellitus; DM,  diabetes mellitus; EEM, external elastic membrane; hs-
* p < 0.025 is signiﬁcant with Bonferroni adjustment: Wilcoxon signed ranks test was ediology 61 (2013) 381–386
effect in plaque volume by atorvastatin in DM patients observed
in this study supports two  previous studies [28,29]. Interestingly,
this inhibitory effect in DM patients for plaque volume regression
was observed in a different period compared to plaque color change
in this study.
Several mechanisms for the inhibitory phenomenon in DM
patients should be considered. A previous study using angioscopy
showed that unstable plaque is detected more frequently in
patients with DM than without DM [30]. In addition, the color grade
of plaque, and the incidence of thrombus is higher in patients with
DM [25]. However, in the present study, signiﬁcant thrombus for-
mation could not be seen in both groups, probably because patients
enrolled were associated with stable CAD, but not with acute coro-
nary syndrome. Furthermore, the angioscopic color grade as well as
total volume of the plaque was not signiﬁcantly different at base-
line between both groups. This might be because yellow plaques
were enrolled under certain criteria of yellowness without know-
ing baseline clinical proﬁles, so it was not surprising that plaques of
both groups had similar color grades. Despite comparable plaque
characteristics at baseline, the reason why there were signiﬁcant
differences of stabilizing effect as well as volume regressive effect
between DM and nDM in the follow-up period might be as follows.
(a) The same intensity of plaque yellowness does not necessarily
represent the same vulnerability. The same color grade might rep-
resent the equivalent thickness of ﬁbrous cap [31], but may  not
correspond to the equivalent content of lipid-core. Actually IVUS
analysis showed that plaque volume in DM tended to be larger
than that in nDM at the baseline in this study. Larger plaque volume
might reﬂect in part plaque vulnerability. (b) It might be possible
that even with the same plaque color and the same plaque volume,
the enrolled plaques in patients with DM might have unique tissue
characteristics at baseline, such as inﬂammatory cell accumula-
tions, or neo-vessels within plaque, or endothelial dysfunction.
There was signiﬁcant decrease in hs-CRP at 80 weeks in nDM
compared to the baseline. The level of hs-CRP in the DM group was
signiﬁcantly higher than in the nDM group.
These ﬁndings suggested that DM patients might have
plaques with an advanced degree of inﬂammation, which might
have delayed the stabilization of plaque by statin, although
p-Value
(nDM vs DM)
Week 80 (n)
[% change]
p-Value (vs
baseline)
p-Value (nDM
vs DM)
0.305
110.63 ± 30.12 (21)
[−19.26 ± 14.44%]
<0.001*
0.074
139.50 ± 49.46 (7)
[−12.95 ± 11.31%]
0.060
0.914
316.99 ± 72.53 (21)
[−6.48 ± 7.19%]
<0.001*
0.943
314.61 ± 84.00 (7)
[−10.88 ± 6.59%]
0.005*
0.601
206.37 ± 61.11 (21)
[3.34 ± 9.60%]
0.381
0.242
175.11 ± 55.34 (7)
[−9.18 ± 10.16%]
0.042
sCRP.
CRP, high sensitivity C-reactive protein.
mployed for hsCRP.
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he stabilizing effect caught up with the nDM group at
eek 80.
It was documented using virtual histology-IVUS that the plaque
omposition of the coronary arteries in patients with DM was
emarkably different from a patient without DM [32]. The ﬁbro-
atty fraction could be observed more frequently in DM compared
o that in nDM. They also demonstrated that calciﬁed area within
laque was larger in DM patients than that in the nDM group. A
tudy using integrated backscatter-IVUS showed that the group
ith DM had signiﬁcantly larger lipid cores and thinner intimal
yperplasia [33]. These differences may  reﬂect the difference in
egressive response to statin.
An attenuated effect of statin on plaque volume reduction in DM
atients was reported by IVUS in a previous study. A sub-analysis of
he JAPAN-ACS study demonstrated that in DM patients with acute
oronary syndrome plaque volume did not regress as much as in
DM patients, although the decrease in LDL-C level at the follow-
p period was comparable between the DM and nDM groups [26].
nteresting results from the study were that there was  a signiﬁcant
orrelation between LDL-C level and the degree of plaque volume
hange in the DM patients but not in the nDM patients. It was spec-
lated that there were two types of plaque regression mechanism
y statins in patients with acute coronary syndrome. One is a LDL-
-dependent mechanism, which may  be predominant in the DM
atients, and another is a LDL-C non-dependent mechanism which
ay  be predominant in the nDM patients. It was suggested that
he presence of DM might be an inhibitory factor for the LDL-C
on-dependent mechanism.
In the DM group, LDL-C decreased to less than 80 mg/dL as well
s in the nDM group. However, the stabilization of yellow plaque
as signiﬁcantly delayed, although the degree of yellow grade of
laques in DM patients decreased to about the same as the nDM
atients. Therefore, intensive lipid-lowering therapy should be per-
ormed at least over 80 weeks. Whether the LDL-C level around
0 mg/dL is sufﬁcient could not be determined by these data. It
ight be possible that the lower LDL-C level less than 80 mg/dL
ight have enhanced stabilization of plaque in DM patients. To
rove this speculation, some prospective randomized study would
e necessary.
linical implications
The present study suggested that in DM patients with stable
AD the plaque stabilizing effect of statins was shown to be atten-
ated and delayed especially during the ﬁrst 28 weeks, but that the
ffect became comparable to nDM patients during the next 1 year.
herefore, statins should be administered in DM patients for a suf-
ciently long time. Our data also gave insight into the mechanism
f plaque regression by statins.
tudy limitation
Since we used multiple imaging devices for single patients,
he number of patients enrolled in this study is limited, so a
arger-scale prospective investigation should be conducted in the
uture. Because a control group was not included, the natural his-
ory of plaques without intervention is unknown. Both IVUS and
ngioscopy are invasive methods, making frequent data acquisi-
ion impossible for ethical reasons. Thus, the effect of statins before
eek 28 or after week 80 is unknown.onclusion
The plaque volume regression by atorvastatin was shown to
e similar in DM and nDM patients, however, the plaque colordiology 61 (2013) 381–386 385
improvement, in other words, plaque stabilizing effect tended to
be delayed in the DM group. These results indicate that patients
with DM should be treated by intensive lipid-lowering therapy with
atorvastatin for at least 80 weeks to stabilize vulnerable plaque
compared with patients without DM.
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